Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	histone H3K36 methyltransferase activity	NSD3 NSD2	3.91e-06	13	5	2	GO:0046975
GeneOntologyMolecularFunction	amino acid:sodium symporter activity	SLC6A8 SLC6A20	1.27e-05	23	5	2	GO:0005283
GeneOntologyMolecularFunction	amino acid:monoatomic cation symporter activity	SLC6A8 SLC6A20	2.03e-05	29	5	2	GO:0005416
GeneOntologyMolecularFunction	modified amino acid transmembrane transporter activity	SLC6A8 SLC6A20	2.64e-05	33	5	2	GO:0072349
GeneOntologyMolecularFunction	organic acid:sodium symporter activity	SLC6A8 SLC6A20	2.97e-05	35	5	2	GO:0005343
GeneOntologyMolecularFunction	histone H3 methyltransferase activity	NSD3 NSD2	4.73e-05	44	5	2	GO:0140938
GeneOntologyMolecularFunction	protein-lysine N-methyltransferase activity	NSD3 NSD2	1.14e-04	68	5	2	GO:0016279
GeneOntologyMolecularFunction	lysine N-methyltransferase activity	NSD3 NSD2	1.17e-04	69	5	2	GO:0016278
GeneOntologyMolecularFunction	histone methyltransferase activity	NSD3 NSD2	1.24e-04	71	5	2	GO:0042054
GeneOntologyMolecularFunction	solute:sodium symporter activity	SLC6A8 SLC6A20	1.61e-04	81	5	2	GO:0015370
GeneOntologyMolecularFunction	organic cation transmembrane transporter activity	SLC6A8 SLC6A20	1.69e-04	83	5	2	GO:0015101
GeneOntologyMolecularFunction	protein methyltransferase activity	NSD3 NSD2	2.61e-04	103	5	2	GO:0008276
GeneOntologyMolecularFunction	N-methyltransferase activity	NSD3 NSD2	2.71e-04	105	5	2	GO:0008170
GeneOntologyMolecularFunction	amino acid transmembrane transporter activity	SLC6A8 SLC6A20	2.71e-04	105	5	2	GO:0015171
GeneOntologyMolecularFunction	solute:monoatomic cation symporter activity	SLC6A8 SLC6A20	3.48e-04	119	5	2	GO:0015294
GeneOntologyMolecularFunction	symporter activity	SLC6A8 SLC6A20	5.52e-04	150	5	2	GO:0015293
GeneOntologyMolecularFunction	sodium ion transmembrane transporter activity	SLC6A8 SLC6A20	7.17e-04	171	5	2	GO:0015081
GeneOntologyMolecularFunction	S-adenosylmethionine-dependent methyltransferase activity	NSD3 NSD2	7.25e-04	172	5	2	GO:0008757
GeneOntologyMolecularFunction	carboxylic acid transmembrane transporter activity	SLC6A8 SLC6A20	1.05e-03	207	5	2	GO:0046943
GeneOntologyMolecularFunction	organic acid transmembrane transporter activity	SLC6A8 SLC6A20	1.06e-03	208	5	2	GO:0005342
GeneOntologyMolecularFunction	methyltransferase activity	NSD3 NSD2	1.11e-03	213	5	2	GO:0008168
GeneOntologyMolecularFunction	transferase activity, transferring one-carbon groups	NSD3 NSD2	1.23e-03	224	5	2	GO:0016741
GeneOntologyMolecularFunction	histone modifying activity	NSD3 NSD2	1.28e-03	229	5	2	GO:0140993
GeneOntologyMolecularFunction	organic anion transmembrane transporter activity	SLC6A8 SLC6A20	2.08e-03	293	5	2	GO:0008514
GeneOntologyMolecularFunction	secondary active transmembrane transporter activity	SLC6A8 SLC6A20	2.13e-03	296	5	2	GO:0015291
GeneOntologyMolecularFunction	active monoatomic ion transmembrane transporter activity	SLC6A8 SLC6A20	2.20e-03	301	5	2	GO:0022853
GeneOntologyMolecularFunction	metal ion transmembrane transporter activity	SLC6A8 SLC6A20	5.16e-03	465	5	2	GO:0046873
GeneOntologyMolecularFunction	active transmembrane transporter activity	SLC6A8 SLC6A20	5.43e-03	477	5	2	GO:0022804
GeneOntologyMolecularFunction	inorganic cation transmembrane transporter activity	SLC6A8 SLC6A20	9.24e-03	627	5	2	GO:0022890
GeneOntologyMolecularFunction	monoatomic cation transmembrane transporter activity	SLC6A8 SLC6A20	1.03e-02	664	5	2	GO:0008324
GeneOntologyMolecularFunction	chromatin binding	NSD2 MSH6	1.27e-02	739	5	2	GO:0003682
GeneOntologyMolecularFunction	inorganic molecular entity transmembrane transporter activity	SLC6A8 SLC6A20	1.33e-02	758	5	2	GO:0015318
GeneOntologyMolecularFunction	monoatomic ion transmembrane transporter activity	SLC6A8 SLC6A20	1.45e-02	793	5	2	GO:0015075
GeneOntologyMolecularFunction	transmembrane transporter activity	SLC6A8 SLC6A20	3.10e-02	1180	5	2	GO:0022857
GeneOntologyMolecularFunction	transporter activity	SLC6A8 SLC6A20	3.65e-02	1289	5	2	GO:0005215
GeneOntologyBiologicalProcess	modified amino acid transport	SLC6A8 SLC6A20	4.43e-05	44	5	2	GO:0072337
GeneOntologyBiologicalProcess	isotype switching	NSD2 MSH6	8.27e-05	60	5	2	GO:0045190
GeneOntologyBiologicalProcess	somatic recombination of immunoglobulin genes involved in immune response	NSD2 MSH6	8.27e-05	60	5	2	GO:0002204
GeneOntologyBiologicalProcess	somatic diversification of immunoglobulins involved in immune response	NSD2 MSH6	8.27e-05	60	5	2	GO:0002208
GeneOntologyBiologicalProcess	somatic recombination of immunoglobulin gene segments	NSD2 MSH6	1.10e-04	69	5	2	GO:0016447
GeneOntologyBiologicalProcess	immunoglobulin production involved in immunoglobulin-mediated immune response	NSD2 MSH6	1.30e-04	75	5	2	GO:0002381
GeneOntologyBiologicalProcess	somatic diversification of immunoglobulins	NSD2 MSH6	1.37e-04	77	5	2	GO:0016445
GeneOntologyBiologicalProcess	somatic cell DNA recombination	NSD2 MSH6	1.55e-04	82	5	2	GO:0016444
GeneOntologyBiologicalProcess	somatic diversification of immune receptors via germline recombination within a single locus	NSD2 MSH6	1.55e-04	82	5	2	GO:0002562
GeneOntologyBiologicalProcess	somatic diversification of immune receptors	NSD2 MSH6	1.91e-04	91	5	2	GO:0002200
GeneOntologyBiologicalProcess	B cell activation involved in immune response	NSD2 MSH6	2.35e-04	101	5	2	GO:0002312
GeneOntologyBiologicalProcess	regulation of DNA recombination	NSD2 MSH6	5.18e-04	150	5	2	GO:0000018
GeneOntologyBiologicalProcess	carboxylic acid transmembrane transport	SLC6A8 SLC6A20	6.11e-04	163	5	2	GO:1905039
GeneOntologyBiologicalProcess	organic acid transmembrane transport	SLC6A8 SLC6A20	6.41e-04	167	5	2	GO:1903825
GeneOntologyBiologicalProcess	amino acid transport	SLC6A8 SLC6A20	8.73e-04	195	5	2	GO:0006865
GeneOntologyBiologicalProcess	sodium ion transmembrane transport	SLC6A8 SLC6A20	9.92e-04	208	5	2	GO:0035725
GeneOntologyBiologicalProcess	methylation	NSD3 NSD2	1.25e-03	234	5	2	GO:0032259
GeneOntologyBiologicalProcess	immunoglobulin mediated immune response	NSD2 MSH6	1.26e-03	235	5	2	GO:0016064
GeneOntologyBiologicalProcess	immunoglobulin production	NSD2 MSH6	1.33e-03	241	5	2	GO:0002377
GeneOntologyBiologicalProcess	B cell mediated immunity	NSD2 MSH6	1.36e-03	244	5	2	GO:0019724
GeneOntologyBiologicalProcess	immune system development	NSD2 MSH6	1.41e-03	248	5	2	GO:0002520
GeneOntologyBiologicalProcess	lymphocyte activation involved in immune response	NSD2 MSH6	1.44e-03	251	5	2	GO:0002285
GeneOntologyBiologicalProcess	sodium ion transport	SLC6A8 SLC6A20	1.72e-03	275	5	2	GO:0006814
GeneOntologyBiologicalProcess	B cell activation	NSD2 MSH6	2.64e-03	341	5	2	GO:0042113
GeneOntologyBiologicalProcess	leukocyte activation involved in immune response	NSD2 MSH6	2.95e-03	361	5	2	GO:0002366
GeneOntologyBiologicalProcess	cell activation involved in immune response	NSD2 MSH6	3.01e-03	365	5	2	GO:0002263
GeneOntologyBiologicalProcess	DNA recombination	NSD2 MSH6	3.06e-03	368	5	2	GO:0006310
GeneOntologyBiologicalProcess	production of molecular mediator of immune response	NSD2 MSH6	3.66e-03	403	5	2	GO:0002440
GeneOntologyBiologicalProcess	carboxylic acid transport	SLC6A8 SLC6A20	3.79e-03	410	5	2	GO:0046942
GeneOntologyBiologicalProcess	organic acid transport	SLC6A8 SLC6A20	3.82e-03	412	5	2	GO:0015849
GeneOntologyBiologicalProcess	lymphocyte mediated immunity	NSD2 MSH6	4.53e-03	449	5	2	GO:0002449
GeneOntologyBiologicalProcess	adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains	NSD2 MSH6	4.79e-03	462	5	2	GO:0002460
GeneOntologyBiologicalProcess	organic anion transport	SLC6A8 SLC6A20	5.92e-03	515	5	2	GO:0015711
GeneOntologyBiologicalProcess	regulation of DNA metabolic process	NSD2 MSH6	7.07e-03	564	5	2	GO:0051052
GeneOntologyBiologicalProcess	leukocyte mediated immunity	NSD2 MSH6	7.36e-03	576	5	2	GO:0002443
GeneOntologyBiologicalProcess	DNA repair	NSD2 MSH6	9.25e-03	648	5	2	GO:0006281
GeneOntologyBiologicalProcess	chromatin remodeling	NSD3 NSD2	1.20e-02	741	5	2	GO:0006338
GeneOntologyBiologicalProcess	adaptive immune response	NSD2 MSH6	1.52e-02	838	5	2	GO:0002250
GeneOntologyBiologicalProcess	immune effector process	NSD2 MSH6	1.59e-02	859	5	2	GO:0002252
GeneOntologyBiologicalProcess	chromatin organization	NSD3 NSD2	1.73e-02	896	5	2	GO:0006325
GeneOntologyBiologicalProcess	inorganic cation transmembrane transport	SLC6A8 SLC6A20	1.82e-02	922	5	2	GO:0098662
GeneOntologyBiologicalProcess	monoatomic cation transmembrane transport	SLC6A8 SLC6A20	1.90e-02	942	5	2	GO:0098655
GeneOntologyBiologicalProcess	DNA damage response	NSD2 MSH6	1.97e-02	959	5	2	GO:0006974
GeneOntologyBiologicalProcess	lymphocyte activation	NSD2 MSH6	2.03e-02	976	5	2	GO:0046649
GeneOntologyBiologicalProcess	protein-DNA complex organization	NSD3 NSD2	2.13e-02	999	5	2	GO:0071824
GeneOntologyCellularComponent	chromatin	NSD3 NSD2 MSH6	3.18e-03	1480	5	3	GO:0000785
GeneOntologyCellularComponent	apical plasma membrane	SLC6A8 SLC6A20	5.17e-03	487	5	2	GO:0016324
GeneOntologyCellularComponent	apical part of cell	SLC6A8 SLC6A20	7.56e-03	592	5	2	GO:0045177
Domain	PWWP	NSD3 NSD2 MSH6	1.05e-08	20	5	3	SM00293
Domain	PWWP	NSD3 NSD2 MSH6	1.63e-08	23	5	3	PF00855
Domain	PWWP_dom	NSD3 NSD2 MSH6	1.63e-08	23	5	3	IPR000313
Domain	PWWP	NSD3 NSD2 MSH6	1.86e-08	24	5	3	PS50812
Domain	AWS	NSD3 NSD2	5.73e-07	5	5	2	PS51215
Domain	AWS_dom	NSD3 NSD2	5.73e-07	5	5	2	IPR006560
Domain	AWS	NSD3 NSD2	5.73e-07	5	5	2	SM00570
Domain	PostSET	NSD3 NSD2	6.87e-06	16	5	2	SM00508
Domain	POST_SET	NSD3 NSD2	6.87e-06	16	5	2	PS50868
Domain	Post-SET_dom	NSD3 NSD2	6.87e-06	16	5	2	IPR003616
Domain	NA_NEUROTRAN_SYMP_2	SLC6A8 SLC6A20	8.76e-06	18	5	2	PS00754
Domain	Na/ntran_symport	SLC6A8 SLC6A20	9.79e-06	19	5	2	IPR000175
Domain	SNF	SLC6A8 SLC6A20	9.79e-06	19	5	2	PF00209
Domain	NA_NEUROTRAN_SYMP_3	SLC6A8 SLC6A20	9.79e-06	19	5	2	PS50267
Domain	NA_NEUROTRAN_SYMP_1	SLC6A8 SLC6A20	9.79e-06	19	5	2	PS00610
Domain	SET	NSD3 NSD2	4.68e-05	41	5	2	PF00856
Domain	SET	NSD3 NSD2	5.91e-05	46	5	2	SM00317
Domain	SET_dom	NSD3 NSD2	6.99e-05	50	5	2	IPR001214
Domain	SET	NSD3 NSD2	6.99e-05	50	5	2	PS50280
Domain	Zinc_finger_PHD-type_CS	NSD3 NSD2	1.18e-04	65	5	2	IPR019786
Domain	PHD	NSD3 NSD2	1.58e-04	75	5	2	PF00628
Domain	Znf_PHD-finger	NSD3 NSD2	1.75e-04	79	5	2	IPR019787
Domain	PHD	NSD3 NSD2	2.22e-04	89	5	2	SM00249
Domain	Znf_PHD	NSD3 NSD2	2.33e-04	91	5	2	IPR001965
Domain	ZF_PHD_2	NSD3 NSD2	2.53e-04	95	5	2	PS50016
Domain	ZF_PHD_1	NSD3 NSD2	2.59e-04	96	5	2	PS01359
Domain	Znf_FYVE_PHD	NSD3 NSD2	6.06e-04	147	5	2	IPR011011
Domain	RING	NSD3 NSD2	2.57e-03	305	5	2	SM00184
Domain	Znf_RING	NSD3 NSD2	2.93e-03	326	5	2	IPR001841
Domain	-	NSD3 NSD2	5.50e-03	449	5	2	3.30.40.10
Domain	Znf_RING/FYVE/PHD	NSD3 NSD2	5.74e-03	459	5	2	IPR013083
Pathway	KEGG_LYSINE_DEGRADATION	NSD3 NSD2	9.46e-05	44	5	2	M13720
Pathway	REACTOME_PKMTS_METHYLATE_HISTONE_LYSINES	NSD3 NSD2	1.04e-04	46	5	2	MM14933
Pathway	REACTOME_PKMTS_METHYLATE_HISTONE_LYSINES	NSD3 NSD2	2.41e-04	70	5	2	M27231
Pathway	WP_NRF2_PATHWAY	SLC6A8 SLC6A20	9.74e-04	141	5	2	M39454
Pathway	REACTOME_CHROMATIN_MODIFYING_ENZYMES	NSD3 NSD2	1.50e-03	175	5	2	MM14941
Pathway	REACTOME_CHROMATIN_MODIFYING_ENZYMES	NSD3 NSD2	3.57e-03	272	5	2	M29619
Pathway	REACTOME_DNA_REPAIR	NSD2 MSH6	4.35e-03	301	5	2	MM15433
Pathway	WP_NUCLEAR_RECEPTORS_METAPATHWAY	SLC6A8 SLC6A20	4.73e-03	314	5	2	M39428
Pathway	REACTOME_DNA_REPAIR	NSD2 MSH6	5.28e-03	332	5	2	M15434
Pubmed	A PWWP Domain of Histone-Lysine N-Methyltransferase NSD2 Binds to Dimethylated Lys-36 of Histone H3 and Regulates NSD2 Function at Chromatin.	NSD3 NSD2 MSH6	5.19e-10	14	5	3	26912663
Pubmed	Targeting H3K36 methyltransferases NSDs: a promising strategy for tumor targeted therapy.	NSD3 NSD2	1.65e-08	2	5	2	34083510
Pubmed	The histone methyltransferase activity of WHISTLE is important for the induction of apoptosis and HDAC1-mediated transcriptional repression.	NSD3 NSD2	4.96e-08	3	5	2	17239852
Pubmed	The methyltransferase NSD3 has chromatin-binding motifs, PHD5-C5HCH, that are distinct from other NSD (nuclear receptor SET domain) family members in their histone H3 recognition.	NSD3 NSD2	4.96e-08	3	5	2	23269674
Pubmed	The NSD family of protein methyltransferases in human cancer.	NSD3 NSD2	4.96e-08	3	5	2	25942451
Pubmed	Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases.	NSD3 NSD2	4.96e-08	3	5	2	33361816
Pubmed	The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors.	NSD3 NSD2	4.96e-08	3	5	2	35532818
Pubmed	Characterization of a novel WHSC1-associated SET domain protein with H3K4 and H3K27 methyltransferase activity.	NSD3 NSD2	4.96e-08	3	5	2	16682010
Pubmed	Histone and DNA binding ability studies of the NSD subfamily of PWWP domains.	NSD3 NSD2	9.92e-08	4	5	2	34271259
Pubmed	Systematic perturbations of SETD2, NSD1, NSD2, NSD3, and ASH1L reveal their distinct contributions to H3K36 methylation.	NSD3 NSD2	1.65e-07	5	5	2	39390582
Pubmed	In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L.	NSD3 NSD2	1.65e-07	5	5	2	25494638
Pubmed	The repertoire of solute carriers of family 6: identification of new human and rodent genes.	SLC6A8 SLC6A20	3.47e-06	21	5	2	16125675
Pubmed	Transcription factor Foxp3 and its protein partners form a complex regulatory network.	NSD3 NSD2 MSH6	1.18e-05	370	5	3	22922362
Pubmed	The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3.	NSD3 NSD2	2.63e-05	57	5	2	21555454
Pubmed	Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains.	NSD3 NSD2 MSH6	3.50e-05	533	5	3	30554943
Pubmed	The in vivo Interaction Landscape of Histones H3.1 and H3.3.	NSD3 NSD2 MSH6	5.18e-05	608	5	3	36089195
Pubmed	ATRX proximal protein associations boast roles beyond histone deposition.	NSD3 NSD2	6.74e-05	91	5	2	34780483
Pubmed	Stabilization of the methyl-CpG binding protein ZBTB38 by the deubiquitinase USP9X limits the occurrence and toxicity of oxidative stress in human cells.	NSD3 MSH6	7.34e-05	95	5	2	29490077
Pubmed	TWIST1 and chromatin regulatory proteins interact to guide neural crest cell differentiation.	NSD3 NSD2	9.67e-05	109	5	2	33554859
Interaction	CDC14B interactions	NSD3 NSD2 MSH6	4.67e-06	158	5	3	int:CDC14B
Interaction	CENPA interactions	NSD3 NSD2 MSH6	6.32e-05	377	5	3	int:CENPA
Interaction	FOXP3 interactions	NSD3 NSD2 MSH6	9.47e-05	432	5	3	int:FOXP3
Interaction	ZNF330 interactions	NSD3 NSD2 MSH6	1.04e-04	446	5	3	int:ZNF330
Interaction	CCDC71 interactions	NSD3 NSD2	1.25e-04	72	5	2	int:CCDC71
Interaction	H3C3 interactions	NSD3 NSD2 MSH6	1.42e-04	495	5	3	int:H3C3
Interaction	RFT1 interactions	SLC6A8 SLC6A20	1.54e-04	80	5	2	int:RFT1
Interaction	COIL interactions	NSD3 NSD2 MSH6	1.96e-04	552	5	3	int:COIL
Interaction	H2BC8 interactions	NSD3 NSD2 MSH6	2.23e-04	576	5	3	int:H2BC8
Interaction	BRD9 interactions	NSD3 MSH6	3.30e-04	117	5	2	int:BRD9
Interaction	DTL interactions	NSD2 MSH6	3.42e-04	119	5	2	int:DTL
Interaction	H2BC21 interactions	NSD3 NSD2 MSH6	3.89e-04	696	5	3	int:H2BC21
Interaction	H3-3A interactions	NSD3 NSD2 MSH6	4.83e-04	749	5	3	int:H3-3A
Interaction	ZBTB38 interactions	NSD3 MSH6	5.07e-04	145	5	2	int:ZBTB38
Interaction	TWIST1 interactions	NSD3 NSD2	6.96e-04	170	5	2	int:TWIST1
Interaction	H3C1 interactions	NSD3 NSD2 MSH6	8.32e-04	901	5	3	int:H3C1
Interaction	MNDA interactions	NSD3 NSD2	8.50e-04	188	5	2	int:MNDA
Interaction	FEN1 interactions	NSD2 MSH6	8.95e-04	193	5	2	int:FEN1
Interaction	CHD8 interactions	NSD3 MSH6	8.95e-04	193	5	2	int:CHD8
Interaction	SORT1 interactions	SLC6A8 NSD2	1.04e-03	208	5	2	int:SORT1
Interaction	NUCKS1 interactions	NSD2 MSH6	1.16e-03	220	5	2	int:NUCKS1
Interaction	RAD51 interactions	NSD3 MSH6	1.39e-03	241	5	2	int:RAD51
Interaction	DGCR8 interactions	NSD2 MSH6	1.40e-03	242	5	2	int:DGCR8
GeneFamily	PWWP domain containing	NSD3 NSD2 MSH6	1.56e-08	22	5	3	1147
GeneFamily	Zinc fingers C2H2-type\|Lysine methyltransferases\|PR/SET domain family	NSD3 NSD2	3.42e-05	34	5	2	487
GeneFamily	PHD finger proteins	NSD3 NSD2	2.43e-04	90	5	2	88
GeneFamily	Solute carriers	SLC6A8 SLC6A20	4.56e-03	395	5	2	752
Coexpression	GAUSSMANN_MLL_AF4_FUSION_TARGETS_G_DN	SLC6A8 NSD2	1.63e-05	34	5	2	M11023
Coexpression	GRESHOCK_CANCER_COPY_NUMBER_UP	NSD3 NSD2 MSH6	1.82e-05	323	5	3	M9150
Coexpression	GAUSSMANN_MLL_AF4_FUSION_TARGETS_G_DN	SLC6A8 NSD2	1.83e-05	36	5	2	MM486
Coexpression	MATTIOLI_MGUS_VS_PCL	NSD2 MSH6	2.31e-04	127	5	2	M10973
Coexpression	GEORGES_TARGETS_OF_MIR192_AND_MIR215	NSD3 NSD2 MSH6	3.73e-04	892	5	3	M18120
Coexpression	WINNEPENNINCKX_MELANOMA_METASTASIS_UP	NSD2 MSH6	3.75e-04	162	5	2	M6387
Coexpression	NAKAYA_PLASMACYTOID_DENDRITIC_CELL_FLUMIST_AGE_18_50YO_7DY_DN	SLC6A8 NSD2 MSH6	3.95e-04	909	5	3	M41018
Coexpression	GSE17974_0.5H_VS_72H_IL4_AND_ANTI_IL12_ACT_CD4_TCELL_DN	NSD2 MSH6	5.48e-04	196	5	2	M4245
Coexpression	GSE2405_HEAT_KILLED_LYSATE_VS_LIVE_A_PHAGOCYTOPHILUM_STIM_NEUTROPHIL_9H_UP	SLC6A8 NSD2	5.65e-04	199	5	2	M6198
Coexpression	GSE360_T_GONDII_VS_M_TUBERCULOSIS_MAC_UP	SLC6A8 MSH6	5.65e-04	199	5	2	M5258
Coexpression	GSE3039_NKT_CELL_VS_ALPHABETA_CD8_TCELL_UP	SLC6A8 MSH6	5.71e-04	200	5	2	M6429
Coexpression	GSE3920_UNTREATED_VS_IFNB_TREATED_ENDOTHELIAL_CELL_UP	NSD3 SLC6A20	5.71e-04	200	5	2	M6686
Coexpression	GSE4748_CTRL_VS_CYANOBACTERIUM_LPSLIKE_STIM_DC_3H_UP	NSD3 SLC6A20	5.71e-04	200	5	2	M6477
Coexpression	GSE1460_DP_THYMOCYTE_VS_NAIVE_CD4_TCELL_CORD_BLOOD_UP	NSD2 MSH6	5.71e-04	200	5	2	M3459
Coexpression	CHICAS_RB1_TARGETS_GROWING	NSD2 MSH6	8.34e-04	242	5	2	M2128
Coexpression	MITSIADES_RESPONSE_TO_APLIDIN_DN	NSD2 MSH6	8.89e-04	250	5	2	M11318
Coexpression	BUSSLINGER_DUODENAL_MATURE_ENTEROCYTES	SLC6A8 SLC6A20	9.54e-04	259	5	2	M40029
Coexpression	DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_DN	SLC6A8 MSH6	1.08e-03	276	5	2	M3063
Coexpression	KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_UP	NSD3 NSD2 MSH6	1.10e-03	1290	5	3	M80
Coexpression	FOURNIER_ACINAR_DEVELOPMENT_LATE_2	NSD2 MSH6	1.12e-03	281	5	2	M4077
Coexpression	TBK1.DF_DN	SLC6A8 NSD3	1.16e-03	286	5	2	M2864
Coexpression	DODD_NASOPHARYNGEAL_CARCINOMA_UP	NSD3 NSD2 MSH6	1.42e-03	1407	5	3	M14427
Coexpression	SMID_BREAST_CANCER_RELAPSE_IN_BONE_DN	NSD2 MSH6	1.49e-03	324	5	2	M2700
Coexpression	BENPORATH_ES_1	SLC6A8 MSH6	2.03e-03	379	5	2	M1871
Coexpression	LAZARO_GENETIC_MOUSE_MODEL_HIGH_GRADE_LARGE_CELL_NEUROENDOCRINE_LUNG_CARCINOMA_UP	NSD2 MSH6	2.28e-03	402	5	2	MM454
Coexpression	VECCHI_GASTRIC_CANCER_EARLY_UP	SLC6A8 NSD2	2.67e-03	436	5	2	M18855
Coexpression	HE_LIM_SUN_FETAL_LUNG_C3_CYCLING_DEFINITIVE_ERYTHROBLAST	SLC6A8 NSD2	2.84e-03	450	5	2	M45747
Coexpression	TOYOTA_TARGETS_OF_MIR34B_AND_MIR34C	NSD3 NSD2	2.89e-03	454	5	2	M19927
Coexpression	SHEDDEN_LUNG_CANCER_POOR_SURVIVAL_A6	NSD2 MSH6	2.94e-03	458	5	2	M8520
Coexpression	LIAO_METASTASIS	SLC6A8 NSD2	4.07e-03	540	5	2	M13809
Coexpression	CHICAS_RB1_TARGETS_SENESCENT	NSD3 MSH6	4.44e-03	565	5	2	M2125
Coexpression	GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_UP	NSD2 MSH6	4.64e-03	578	5	2	M2368
Coexpression	GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_UP	NSD2 MSH6	4.95e-03	597	5	2	MM1309
Coexpression	GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP	SLC6A8 MSH6	5.18e-03	611	5	2	M1106
Coexpression	CAIRO_HEPATOBLASTOMA_CLASSES_UP	NSD2 MSH6	5.19e-03	612	5	2	M4772
Coexpression	TABULA_MURIS_SENIS_SKIN_EPIDERMAL_CELL_AGEING	SLC6A8 NSD3	5.29e-03	618	5	2	MM3829
Coexpression	GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP	SLC6A8 MSH6	5.79e-03	647	5	2	MM981
Coexpression	SMID_BREAST_CANCER_BASAL_UP	NSD2 MSH6	6.05e-03	662	5	2	M8124
Coexpression	LAZARO_GENETIC_MOUSE_MODEL_HIGH_GRADE_SMALL_CELL_NEUROENDOCRINE_LUNG_CARCINOMA_UP	NSD2 MSH6	6.38e-03	680	5	2	MM456
Coexpression	HE_LIM_SUN_FETAL_LUNG_C4_CYCLING_NK_CELL	NSD2 MSH6	6.64e-03	694	5	2	M45767
Coexpression	FOURATI_BLOOD_TWINRIX_AGE_25_83YO_RESPONDERS_VS_POOR_RESPONDERS_0DY_DN	SLC6A8 NSD3	7.64e-03	746	5	2	M40863
Coexpression	PUJANA_CHEK2_PCC_NETWORK	NSD2 MSH6	7.94e-03	761	5	2	M11961
Coexpression	JOHNSTONE_PARVB_TARGETS_3_DN	NSD3 MSH6	1.05e-02	877	5	2	M2241
Coexpression	HE_LIM_SUN_FETAL_LUNG_C4_CYCLING_T_CELL	NSD2 MSH6	1.19e-02	939	5	2	M45768
Coexpression	KRIGE_RESPONSE_TO_TOSEDOSTAT_6HR_DN	NSD3 MSH6	1.22e-02	950	5	2	M19907
Coexpression	FISCHER_DREAM_TARGETS	NSD2 MSH6	1.27e-02	969	5	2	M149
Coexpression	TABULA_MURIS_SENIS_SKIN_BASAL_CELL_OF_EPIDERMIS_AGEING	SLC6A8 NSD3	1.36e-02	1005	5	2	MM3827
Coexpression	TABULA_MURIS_SENIS_BRAIN_NON_MYELOID_OLIGODENDROCYTE_AGEING	SLC6A8 NSD3	1.73e-02	1139	5	2	MM3690
Coexpression	GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP	SLC6A8 MSH6	1.76e-02	1151	5	2	M1103
ToppCell	TCGA-Bone_and_Soft_Tissue-Primary_Tumor-Sarcoma-Poorly_Differentiated_or_Epithelioid_Leiomyosarcoma\|TCGA-Bone_and_Soft_Tissue / Sample_Type by Project: Shred V9	SLC6A8 MSH6	1.13e-04	152	5	2	6f9c343669883618cd9c1c8921a90c34d153f303
ToppCell	TCGA-Lung-Primary_Tumor-Lung_Carcinoma-Lung_Squamous_Cell_Carcinoma-3\|TCGA-Lung / Sample_Type by Project: Shred V9	SLC6A8 MSH6	1.65e-04	184	5	2	ea4ccebe2d54279fcc517e4f0bfa652b91a808bb
ToppCell	PBMC-Severe-cDC_12\|Severe / Compartment, Disease Groups and Clusters	NSD2 MSH6	1.76e-04	190	5	2	84ee185939bdefb10705b621a70da27701eadcee
ToppCell	droplet-Spleen-SPLEEN-30m-Lymphocytic-immature_NKT_cell\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SLC6A8 NSD2	1.78e-04	191	5	2	c8b99bd3a30c81ee4deba9cbf0196920ab3ab550
ToppCell	3'-GW_trimst-1.5-SmallIntestine-Epithelial\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SLC6A8 SLC6A20	1.91e-04	198	5	2	ecdef1a0a0b8399e193b922c8ca8c25e63de4a4f
ToppCell	3'-GW_trimst-1.5-SmallIntestine-Epithelial-mature_enterocytic-Enterocyte\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SLC6A8 SLC6A20	1.93e-04	199	5	2	f26c20f5d7470e90eaa79613d0b87bd4865585a8
ToppCell	5'-GW_trimst-2-SmallIntestine-Epithelial\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SLC6A8 SLC6A20	1.93e-04	199	5	2	914f66e2b4af323d09fa2340a39cf8051d00a422
ToppCell	3'-GW_trimst-1.5-SmallIntestine-Epithelial-mature_enterocytic\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SLC6A8 SLC6A20	1.93e-04	199	5	2	a10768e1cddd2d38291c30d24820a94040a72211
ToppCell	COVID_non-vent-Lymphocytic-Proliferative_Lymphocyte-\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	NSD2 MSH6	1.95e-04	200	5	2	04bf9e6a0fbd792b49eed63dabba5d6fafed8c07
ToppCell	COVID_vent-Lymphocytic-Proliferative_Lymphocyte-\|COVID_vent / Disease condition, Lineage, Cell class and subclass	NSD2 MSH6	1.95e-04	200	5	2	7e4c0db43a03ca11380a54f44a3cf1991e055b80
ToppCell	5'-GW_trimst-2-SmallIntestine-Epithelial-mature_enterocytic-Enterocyte\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SLC6A8 SLC6A20	1.95e-04	200	5	2	3e13c9a4ba99a7dfbf738b0fb63fb54b4dee5897
ToppCell	5'-GW_trimst-2-SmallIntestine-Epithelial-mature_enterocytic\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SLC6A8 SLC6A20	1.95e-04	200	5	2	73bfdf068a8ecbefc1e6afe9686df73658ee042f
ToppCell	COVID_vent-Lymphocytic-Proliferative_Lymphocyte\|COVID_vent / Disease condition, Lineage, Cell class and subclass	NSD2 MSH6	1.95e-04	200	5	2	9775ca7dedb76fcbb74f80f86b33c94e394c320a
ToppCell	COVID_non-vent-Lymphocytic-Proliferative_Lymphocyte\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	NSD2 MSH6	1.95e-04	200	5	2	f6b5320cdfe640a71e6e2df26f30d42e64b1c921
Drug	Pyrvinium pamoate [3546-41-6]; Down 200; 3.4uM; HL60; HT_HG-U133A	SLC6A8 NSD2 MSH6	4.88e-06	181	5	3	2957_DN
Drug	Piperine [94-62-2]; Down 200; 14uM; MCF7; HT_HG-U133A	SLC6A8 NSD2 MSH6	5.83e-06	192	5	3	4830_DN
Drug	Cyclobenzaprine hydrochloride [6202-23-9]; Down 200; 12.8uM; MCF7; HT_HG-U133A	SLC6A8 NSD2 MSH6	6.20e-06	196	5	3	4834_DN
Drug	Mephentermine hemisulfate [1212-72-2]; Down 200; 9.4uM; PC3; HT_HG-U133A	NSD3 NSD2 MSH6	6.20e-06	196	5	3	3685_DN
Drug	Pergolide mesylate [66104-23-2]; Up 200; 9.8uM; PC3; HT_HG-U133A	NSD3 NSD2 MSH6	6.20e-06	196	5	3	7271_UP
Drug	GSK-3 Inhibitor IX; Down 200; 0.5uM; MCF7; HT_HG-U133A	NSD3 NSD2 MSH6	6.40e-06	198	5	3	6589_DN
Drug	guanidinoacetate	SLC6A8 SLC6A20	5.09e-05	52	5	2	CID000000763
Drug	tricarballylate	NSD3 NSD2	6.57e-05	59	5	2	CID000014925
Drug	NSC407322	SLC6A8 MSH6	3.25e-04	131	5	2	CID000003977
Drug	Digitoxigenin [143-62-4]; Up 200; 10.6uM; MCF7; HT_HG-U133A	SLC6A8 NSD3	5.15e-04	165	5	2	3275_UP
Drug	Strophanthidin [66-28-4]; Up 200; 9.8uM; MCF7; HT_HG-U133A	SLC6A8 NSD3	5.33e-04	168	5	2	6087_UP
Drug	Cephaeline dihydrochloride heptahydrate [6487-30-5]; Down 200; 6uM; HL60; HT_HG-U133A	SLC6A8 NSD2	5.53e-04	171	5	2	2429_DN
Drug	Phenoxybenzamine hydrochloride [63-92-3]; Down 200; 11.8uM; PC3; HT_HG-U133A	NSD2 MSH6	5.92e-04	177	5	2	4652_DN
Drug	1,5-AG	NSD2 MSH6	6.26e-04	182	5	2	CID000064960
Drug	Puromycin dihydrochloride [58-58-2]; Down 200; 7.4uM; PC3; HT_HG-U133A	NSD2 MSH6	6.46e-04	185	5	2	6711_DN
Drug	Cefadroxil [50370-12-2]; Down 200; 11uM; HL60; HT_HG-U133A	NSD2 MSH6	6.53e-04	186	5	2	1323_DN
Drug	Progesterone [57-83-0]; Down 200; 12.8uM; HL60; HT_HG-U133A	SLC6A8 NSD3	6.53e-04	186	5	2	2426_DN
Drug	AG-1478; Down 200; 31.6uM; MCF7; HT_HG-U133A_EA	NSD2 MSH6	6.60e-04	187	5	2	1141_DN
Drug	Picrotoxinin [17617-45-7]; Down 200; 13.6uM; HL60; HT_HG-U133A	NSD2 MSH6	6.67e-04	188	5	2	2161_DN
Drug	Primaquine diphosphate [63-45-6]; Down 200; 8.8uM; MCF7; HT_HG-U133A	NSD2 MSH6	6.67e-04	188	5	2	4845_DN
Drug	Promethazine hydrochloride [58-33-3]; Down 200; 12.4uM; PC3; HT_HG-U133A	NSD2 MSH6	6.74e-04	189	5	2	6717_DN
Drug	Mitoxantrone dihydrochloride [70476-82-3]; Up 200; 7.8uM; MCF7; HT_HG-U133A	SLC6A8 SLC6A20	6.81e-04	190	5	2	3232_UP
Drug	Deptropine citrate [2169-75-7]; Down 200; 7.6uM; HL60; HT_HG-U133A	NSD2 MSH6	6.81e-04	190	5	2	3144_DN
Drug	Prostaglandin E1; Up 200; 10uM; PC3; HT_HG-U133A	NSD2 MSH6	6.81e-04	190	5	2	6571_UP
Drug	Paclitaxel [33069-62-4]; Down 200; 4.6uM; PC3; HT_HG-U133A	NSD2 MSH6	6.89e-04	191	5	2	6720_DN
Drug	Diphenylpyraline hydrochloride [132-18-3]; Down 200; 12.6uM; PC3; HT_HG-U133A	NSD2 MSH6	6.89e-04	191	5	2	4299_DN
Drug	Nitrofural [59-87-0]; Down 200; 20.2uM; PC3; HT_HG-U133A	SLC6A8 NSD2	6.89e-04	191	5	2	6721_DN
Drug	2-propylpentanoic acid; Down 200; 200uM; HL60; HT_HG-U133A	NSD2 MSH6	6.89e-04	191	5	2	6173_DN
Drug	Flunixin meglumine [42461-84-7]; Down 200; 8.2uM; PC3; HT_HG-U133A	NSD3 NSD2	6.89e-04	191	5	2	4273_DN
Drug	0317956-0000 [391210-11-0]; Down 200; 1uM; PC3; HT_HG-U133A	SLC6A20 MSH6	6.96e-04	192	5	2	4334_DN
Drug	PNU-0293363 [326823-19-2]; Up 200; 10uM; MCF7; HT_HG-U133A	NSD2 MSH6	6.96e-04	192	5	2	6573_UP
Drug	Tracazolate hydrochloride [41094-88-6]; Down 200; 11.8uM; HL60; HT_HG-U133A	SLC6A8 NSD3	6.96e-04	192	5	2	2919_DN
Drug	Triprolidine hydrochloride [550-70-9]; Up 200; 12.8uM; PC3; HT_HG-U133A	NSD3 NSD2	6.96e-04	192	5	2	7248_UP
Drug	Triflupromazine hydrochloride [1098-60-8]; Down 200; 10.2uM; MCF7; HT_HG-U133A	SLC6A8 NSD3	6.96e-04	192	5	2	7466_DN
Drug	Hesperidin [520-26-3]; Down 200; 6.6uM; PC3; HT_HG-U133A	NSD2 MSH6	6.96e-04	192	5	2	6714_DN
Drug	Rapamycin; Up 200; 0.1uM; MCF7; HT_HG-U133A	NSD3 SLC6A20	6.96e-04	192	5	2	5218_UP
Drug	PF-00562151-00 [351320-12-2]; Down 200; 10uM; PC3; HT_HG-U133A	NSD3 NSD2	6.96e-04	192	5	2	5959_DN
Drug	Cephalexin monohydrate [23325-78-2]; Down 200; 11uM; HL60; HT_HG-U133A	NSD2 MSH6	6.96e-04	192	5	2	1273_DN
Drug	Pipemidic acid [51940-44-4]; Down 200; 13.2uM; PC3; HT_HG-U133A	NSD2 MSH6	6.96e-04	192	5	2	6752_DN
Drug	Enilconazole [35554-44-0]; Down 200; 13.4uM; HL60; HT_HG-U133A	SLC6A8 NSD3	7.03e-04	193	5	2	3139_DN
Drug	Gramine [87-52-5]; Up 200; 23uM; MCF7; HT_HG-U133A	NSD3 SLC6A20	7.03e-04	193	5	2	4118_UP
Drug	Glycocholic acid [475-31-0]; Down 200; 8.6uM; PC3; HT_HG-U133A	NSD2 MSH6	7.03e-04	193	5	2	6716_DN
Drug	Carisoprodol [78-44-4]; Up 200; 15.4uM; MCF7; HT_HG-U133A	NSD3 MSH6	7.03e-04	193	5	2	3251_UP
Drug	Amiodarone hydrochloride [19774-82-4]; Up 200; 5.8uM; MCF7; HT_HG-U133A	NSD3 SLC6A20	7.03e-04	193	5	2	3296_UP
Drug	Naphazoline hydrochloride [550-99-2]; Down 200; 16.2uM; PC3; HT_HG-U133A	NSD3 NSD2	7.03e-04	193	5	2	6604_DN
Drug	Ceforanide [60925-61-3]; Down 200; 7.6uM; PC3; HT_HG-U133A	SLC6A8 NSD2	7.03e-04	193	5	2	6751_DN
Drug	Carbetapentane citrate [23142-01-0]; Down 200; 7.6uM; HL60; HT_HG-U133A	NSD3 NSD2	7.03e-04	193	5	2	1268_DN
Drug	Haloperidol [52-86-8]; Up 200; 10.6uM; PC3; HT_HG-U133A	NSD2 SLC6A20	7.10e-04	194	5	2	4678_UP
Drug	Moxalactam disodium salt [64953-12-4]; Down 200; 7uM; PC3; HT_HG-U133A	NSD2 MSH6	7.10e-04	194	5	2	4648_DN
Drug	Ungerine nitrate; Down 200; 10.2uM; MCF7; HT_HG-U133A	SLC6A8 SLC6A20	7.10e-04	194	5	2	6076_DN
Drug	Benserazide hydrochloride [14919-77-8]; Down 200; 13.6uM; PC3; HT_HG-U133A	SLC6A8 NSD2	7.10e-04	194	5	2	6722_DN
Drug	Nifedipine [21829-25-4]; Up 200; 11.6uM; PC3; HT_HG-U133A	NSD3 NSD2	7.10e-04	194	5	2	1814_UP
Drug	2-propylpentanoic acid; Up 200; 50uM; MCF7; HT_HG-U133A_EA	SLC6A8 NSD3	7.10e-04	194	5	2	1060_UP
Drug	Hexestrol [84-16-2]; Down 200; 14.8uM; HL60; HT_HG-U133A	SLC6A8 NSD2	7.10e-04	194	5	2	2515_DN
Drug	Scopoletin [92-61-5]; Up 200; 20.8uM; MCF7; HT_HG-U133A	NSD2 SLC6A20	7.10e-04	194	5	2	6510_UP
Drug	Nitrofurantoin [67-20-9]; Down 200; 16.8uM; PC3; HT_HG-U133A	NSD3 NSD2	7.10e-04	194	5	2	3674_DN
Drug	Thonzonium bromide [553-08-2]; Down 200; 6.8uM; PC3; HT_HG-U133A	NSD2 MSH6	7.10e-04	194	5	2	4617_DN
Drug	Primidone [125-33-7]; Down 200; 18.4uM; PC3; HT_HG-U133A	SLC6A8 NSD2	7.10e-04	194	5	2	6723_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NSD2 MSH6	7.10e-04	194	5	2	5017_DN
Drug	Butoconazole nitrate [32872-77-1]; Down 200; 8.4uM; HL60; HT_HG-U133A	SLC6A8 NSD3	7.10e-04	194	5	2	2427_DN
Drug	16-phenyl tetranor Prostaglandin E2; Down 200; 10uM; PC3; HT_HG-U133A	NSD2 MSH6	7.18e-04	195	5	2	7509_DN
Drug	Arecoline hydrobromide [300-08-3]; Down 200; 17uM; HL60; HT_HG-U133A	NSD2 MSH6	7.18e-04	195	5	2	1303_DN
Drug	Cyclobenzaprine hydrochloride [6202-23-9]; Up 200; 12.8uM; MCF7; HT_HG-U133A	SLC6A8 NSD3	7.18e-04	195	5	2	3268_UP
Drug	Beta-sistosterol [83-46-5]; Down 200; 9.6uM; PC3; HT_HG-U133A	NSD3 SLC6A20	7.18e-04	195	5	2	4073_DN
Drug	Indapamide [26807-65-8]; Down 200; 10.6uM; PC3; HT_HG-U133A	NSD3 NSD2	7.18e-04	195	5	2	3778_DN
Drug	Rapamycin; Down 200; 0.1uM; HL60; HT_HG-U133A	SLC6A8 NSD2	7.18e-04	195	5	2	1162_DN
Drug	Erythromycin [114-07-8]; Down 200; 5.4uM; PC3; HG-U133A	SLC6A8 NSD2	7.18e-04	195	5	2	1928_DN
Drug	Spironolactone [52-01-7]; Up 200; 9.6uM; PC3; HT_HG-U133A	SLC6A8 NSD2	7.18e-04	195	5	2	2064_UP
Drug	PHA-00665752 [477575-56-7]; Down 200; 10uM; MCF7; HT_HG-U133A	NSD2 MSH6	7.18e-04	195	5	2	6578_DN
Drug	Thioguanosine [85-31-4]; Down 200; 12.6uM; PC3; HT_HG-U133A	NSD2 MSH6	7.18e-04	195	5	2	6643_DN
Drug	Furazolidone [67-45-8]; Down 200; 17.8uM; MCF7; HT_HG-U133A	SLC6A8 NSD3	7.18e-04	195	5	2	3358_DN
Drug	Etifenin [63245-28-3]; Up 200; 12.4uM; PC3; HT_HG-U133A	SLC6A8 SLC6A20	7.25e-04	196	5	2	3998_UP
Drug	PNU-0293363 [326823-19-2]; Up 200; 10uM; PC3; HT_HG-U133A	NSD2 MSH6	7.25e-04	196	5	2	6568_UP
Drug	PHA-00767505E [723337-45-9]; Down 200; 10uM; MCF7; HT_HG-U133A	NSD2 MSH6	7.25e-04	196	5	2	6596_DN
Drug	Letrozole [112809-51-5]; Up 200; 14uM; MCF7; HT_HG-U133A	NSD2 MSH6	7.25e-04	196	5	2	4824_UP
Drug	Acyclovir [59277-89-3]; Up 200; 17.8uM; PC3; HT_HG-U133A	NSD3 NSD2	7.25e-04	196	5	2	4683_UP
Drug	6-Furfurylaminopurine [525-79-1]; Down 200; 18.6uM; HL60; HT_HG-U133A	NSD2 MSH6	7.25e-04	196	5	2	2511_DN
Drug	Calciferol [50-14-6]; Up 200; 10uM; HL60; HT_HG-U133A	NSD2 MSH6	7.25e-04	196	5	2	2442_UP
Drug	Pyrantel tartrate [33401-94-4]; Up 200; 11.2uM; PC3; HT_HG-U133A	NSD3 SLC6A20	7.25e-04	196	5	2	5088_UP
Drug	Ioxaglic acid [59017-64-0]; Down 200; 3.2uM; MCF7; HT_HG-U133A	SLC6A8 NSD3	7.25e-04	196	5	2	7470_DN
Drug	Gly-His-Lys acetate salt; Up 200; 1uM; PC3; HT_HG-U133A	NSD2 MSH6	7.25e-04	196	5	2	6570_UP
Drug	Antazoline hydrochloride [2508-72-7]; Up 200; 13.2uM; PC3; HT_HG-U133A	NSD3 NSD2	7.25e-04	196	5	2	7128_UP
Drug	Niflumic acid [4394-00-7]; Down 200; 14.2uM; MCF7; HT_HG-U133A	SLC6A8 NSD3	7.25e-04	196	5	2	7430_DN
Drug	Tetracycline hydrochloride [64-75-5]; Up 200; 8.4uM; PC3; HT_HG-U133A	SLC6A8 NSD2	7.25e-04	196	5	2	2080_UP
Drug	Orlistat; Down 200; 10uM; MCF7; HT_HG-U133A	NSD2 MSH6	7.25e-04	196	5	2	6905_DN
Drug	Azaperone [1649-18-9]; Down 200; 12.2uM; PC3; HT_HG-U133A	SLC6A8 NSD3	7.25e-04	196	5	2	5877_DN
Drug	Mecamylamine hydrochloride [826-39-1]; Up 200; 19.6uM; PC3; HT_HG-U133A	NSD3 MSH6	7.25e-04	196	5	2	7263_UP
Drug	Guaifenesin [93-14-1]; Up 200; 20.2uM; MCF7; HT_HG-U133A	NSD3 NSD2	7.32e-04	197	5	2	3431_UP
Drug	Menadione [58-27-5]; Down 200; 23.2uM; HL60; HT_HG-U133A	NSD3 MSH6	7.32e-04	197	5	2	2439_DN
Drug	Dihydrostreptomycin sulfate [5490-27-7]; Up 200; 2.8uM; PC3; HT_HG-U133A	NSD3 SLC6A20	7.32e-04	197	5	2	5751_UP
Drug	Bepridil hydrochloride [74764-40-2]; Down 200; 10uM; PC3; HT_HG-U133A	NSD2 MSH6	7.32e-04	197	5	2	4613_DN
Drug	Scopolamine hydrochloride [55-16-3]; Up 200; 11.8uM; MCF7; HT_HG-U133A	SLC6A8 MSH6	7.32e-04	197	5	2	4803_UP
Drug	ionomycin calcium salt; Down 200; 2uM; MCF7; HT_HG-U133A_EA	NSD2 MSH6	7.32e-04	197	5	2	882_DN
Disease	Sotos syndrome 1 (implicated_via_orthology)	NSD3 NSD2	6.89e-08	3	5	2	DOID:0112103 (implicated_via_orthology)
Disease	syndrome (implicated_via_orthology)	NSD3 NSD2	3.51e-06	18	5	2	DOID:225 (implicated_via_orthology)
Disease	Intellectual Disability	SLC6A8 NSD2	2.22e-03	447	5	2	C3714756

Protein segments in the cluster

Peptide	Gene	Start	Entry
VWSKVSGYPWWPCMV	NSD2	226	O96028
VWAKMEGYPWWPCLV	MSH6	96	P52701
IGYRPCPWMKWCWSF	SLC6A8	511	P48029
VSWYWKVMWAGVSPL	SLC6A20	501	Q9NP91
SKVGTYPWWPCMVSS	NSD3	276	Q9BZ95